ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SCLP Scancell Holdings Plc

11.125
1.13 (11.25%)
25 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Scancell Holdings Plc LSE:SCLP London Ordinary Share GB00B63D3314 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.13 11.25% 11.125 10.75 11.50 11.125 9.875 10.00 1,642,507 15:25:22
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 5.27M -11.94M -0.0129 -8.62 103.17M
Scancell Holdings Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SCLP. The last closing price for Scancell was 10p. Over the last year, Scancell shares have traded in a share price range of 7.65p to 18.125p.

Scancell currently has 927,819,977 shares in issue. The market capitalisation of Scancell is £103.17 million. Scancell has a price to earnings ratio (PE ratio) of -8.62.

Scancell Share Discussion Threads

Showing 63126 to 63149 of 67525 messages
Chat Pages: Latest  2533  2532  2531  2530  2529  2528  2527  2526  2525  2524  2523  2522  Older
DateSubjectAuthorDiscuss
19/9/2023
08:28
just to put that into context ......... if i had been wrong it would have cost me £130,000 of capital

as big mama says Money talks

LOL

inanaco
19/9/2023
08:21
and scancell did it as a standalone ..........
inanaco
19/9/2023
08:18
. In a Phase 1/2 clinical trial, 14 out of 16 resected
patients (89%) survived for more than 5 years following vaccination with SCIB1.
The original Phase 2 study was designed to assess whether the addition of SCIB1 treatment to pembrolizumab results in an improvement in patient outcomes for patients with metastatic disease.

marcusl2
19/9/2023
08:15
For any newbies, Scib is off the shelf. Merck / Moderna is personalised.

iScib with Avidimab will be a further improvement and cover ALL patients.

marcusl2
19/9/2023
08:14
Marcus scancell from memory was 88% in the same setting "resected"
inanaco
19/9/2023
08:14
Plasbryn - IMO the endpoint for the impact of this data will not be diminished in any way by the release today of this RNS . . . an alternative view would be that matters are now nicely primed for Prof. Lindy at Cicon Milan - Scancell are ready to turn on the afterburners later this week.
torquayfan
19/9/2023
08:13
Plenty of the big boys will want Immunobody and Avidimab. Don`t forget about Moditope and the Glymabs !!
marcusl2
19/9/2023
08:11
Moderna and Merck’s Cancer Vaccine Cuts Risk of Recurrence or Death 44% in Late-Stage, High-Risk Melanoma After Resection


Scancell...

Key Highlights

-- SCOPE trial surpasses its first milestone with an 82% response rate
-- To our knowledge no other combination has achieved this response rate with doublet checkpoint inhibitors in unresectable metastatic melanoma


( one is resected the other unresected )

marcusl2
19/9/2023
08:08
Vastly derisked data here. Very nice. Should really move on higher. Half the mcap of AVCT and more advanced?Of course you get sell on news brigade but really good update.
babbler
19/9/2023
08:06
Plasbryn,They were always going to have to update the market on the SBIB data - and indeed they said they would.Question is, will there be a Modi-1 update too?On the "market price" aspect, we are getting closer to having a properly-informed market. The last few months are now being proven to have been irrelevant, as I'd pointed out - simply because nobody who was buying or selling knew the trial data.
markingtime
19/9/2023
08:01
10 years of Scib1 ....... no risk

which one has failed posts

LOL

devastating news for the "this is risky brigade"

i also told you SCIB1 is the backstop ........... and explained why

inanaco
19/9/2023
07:58
Ruck - re. "I wonder if the RNS had to be brought forward because the cat was out the bag? " Good point but I guess it would be hard to contain news of this significance.

I doubt that the endpoint for the 'impact' will be any lower because of this RNS today.

torquayfan
19/9/2023
07:57
yes that will be a shocker for merck and moderna
inanaco
19/9/2023
07:56
Move over Merck and mRNA, here comes Lindy
marcusl2
19/9/2023
07:55
Who said anything about £15-20mn, Bermuda?Clearly I was talking about number of shares.
markingtime
19/9/2023
07:54
firestarter ....... you are not very good at this are you
inanaco
19/9/2023
07:54
News clearly known over the weekend given immediate buying on open. However, news was only known to a small section of the market - rise should continue.
nigelpm
19/9/2023
07:53
i am sure you would like my holding at 7.59 am ....

ruck

inanaco
19/9/2023
07:53
Sell on news as this has already risen yesterday 50% nowExpect the insiders to dump
firestarter1
19/9/2023
07:52
trinity will need to revalue
inanaco
19/9/2023
07:51
"go all in verified"We are a long way from that lol.
ruckrover
19/9/2023
07:51
A stunning RNS on what is a difficult cancer to control.
This is top draw research and now what looks certain delivery.

rogerbridge
19/9/2023
07:51
Ivy is colin from accounts
inanaco
19/9/2023
07:50
Ruck - re. your objection - "And all you can do is gloat?" . . . would it be fair to say "And all YOU can do is carp?" ??

Anyway - who is 'Colin from Accounts' ?

torquayfan
Chat Pages: Latest  2533  2532  2531  2530  2529  2528  2527  2526  2525  2524  2523  2522  Older